Genexine Inc (095700):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Genexine Inc (095700) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C7983
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:33
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:韓国
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Genexine Inc (Genexine), formerly Genexine Co Ltd is a clinical stage biotechnology company that develops and commercialize immunotherapeutics and next generation novel long-acting biologics. The company develops therapeutic vaccines for incurable diseases and next-generation antibody fusion protein drugs. Its pipeline products include GX-H9, GX-G8, GX-30, GX-188E, GX-17, GX-P2, GX-E2, GX-G3, and GX-G6. Genexine develops products for various therapeutic areas such as orphans, cancers and immune disorders. The company uses hybrid Fc technology platform for the discovery of a wide range of differentiated agonistic protein therapeutics. It partners with other pharmaceutical companies for its research and development activities. The company has operations in the US and South Korea. Genexine is headquartered in Seongnam, South Korea.

Genexine Inc (095700) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Genexine Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Genexine Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Genexine Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Genexine Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Genexine Inc, Medical Devices Deals, 2012 to YTD 2018 9
Genexine Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Genexine Inc, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Genexine Enters into Licensing Agreement with PharmaJet 11
NeoImmuneTech and Genexine Enter into Agreement with Roche 12
Genexine Enters into Clinical Research Agreement with Merck 13
Tasly Pharma to Form Joint Venture with CBC SPVII and Genexine 14
I-Bridge Capital, Shanghai Tasly Pharma and Genexine Form Joint Venture 15
Kalbe Farma and Genexine Form Joint Venture 16
Genexine and Ilko Ilac Form Joint Venture 17
Licensing Agreements 18
I-Mab Biopharma Enters into Licensing Agreement with Genexine 18
Shanghai ChemoWanbang Biopharma Enters into Licensing Agreement with Genexine 19
Tasly Pharma Enters into Licensing Agreement with Genexine 20
Equity Offering 21
Genexine Raises USD53 Million in Private Placement of Preferred Stock 21
Genexine to Raise USD17 Million in Private Placement of Shares 23
Debt Offering 24
Genexine Raises USD17.8 Million in Private Placement of Bonds 24
Genexine Inc – Key Competitors 25
Genexine Inc – Key Employees 26
Genexine Inc – Locations And Subsidiaries 27
Head Office 27
Other Locations & Subsidiaries 27
Joint Venture 27
Recent Developments 28
Product News 28
07/18/2018: Hyleukin-7 selected as a Korea Drug Development Fund project for combination trial with Merck’s KEYTRUDA 28
06/19/2017: Genexine Receives Approval to Initiate Phase Ib/II Trial of GX-188E, HPV Therapeutic DNA Vaccine, in Combination With KEYTRUDA, for the Treatment of HPV-Induced Cervical Cancer 29
Clinical Trials 30
May 29, 2018: NeoImmuneTech Announces Initiation of HyLeukin-7 Clinical Development for Cancer Patients in the U.S. 30
Apr 03, 2017: Genexine Releases Positive Interim Phase 2 Clinical Data from PGHD Trial with long-acting growth hormone, GX-H9 at ENDO 2017 31
Jan 18, 2017: GX-G6 for Type 2 Diabetes, Receives Phase I IND Approval in Europe 32
Appendix 33
Methodology 33
About GlobalData 33
Contact Us 33
Disclaimer 33

List of Tables
Genexine Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Genexine Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Genexine Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Genexine Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Genexine Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Genexine Inc, Medical Devices Deals, 2012 to YTD 2018 9
Genexine Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Genexine Enters into Licensing Agreement with PharmaJet 11
NeoImmuneTech and Genexine Enter into Agreement with Roche 12
Genexine Enters into Clinical Research Agreement with Merck 13
Tasly Pharma to Form Joint Venture with CBC SPVII and Genexine 14
I-Bridge Capital, Shanghai Tasly Pharma and Genexine Form Joint Venture 15
Kalbe Farma and Genexine Form Joint Venture 16
Genexine and Ilko Ilac Form Joint Venture 17
I-Mab Biopharma Enters into Licensing Agreement with Genexine 18
Shanghai ChemoWanbang Biopharma Enters into Licensing Agreement with Genexine 19
Tasly Pharma Enters into Licensing Agreement with Genexine 20
Genexine Raises USD53 Million in Private Placement of Preferred Stock 21
Genexine to Raise USD17 Million in Private Placement of Shares 23
Genexine Raises USD17.8 Million in Private Placement of Bonds 24
Genexine Inc, Key Competitors 25
Genexine Inc, Key Employees 26
Genexine Inc, Other Locations 27
Genexine Inc, Joint Venture 27

List of Figures
Genexine Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Genexine Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Genexine Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Genexine Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Genexine Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Genexine Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Genexine Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Genexine Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Genexine Inc, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Genexine Inc (095700):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Summit Hotel Properties Inc:企業のM&A・事業提携・投資動向
    Summit Hotel Properties Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Summit Hotel Properties Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acq …
  • Mylan N.V.:企業のM&A・事業提携・投資動向
    Mylan N.V. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Mylan N.V. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capi …
  • US WorldMeds LLC:製薬・医療:M&Aディール及び事業提携情報
    Summary US WorldMeds LLC (US WorldMeds) is a specialty pharmaceutical company that develops, licenses and markets healthcare products to improve lives of patients with challenging conditions and unmet medical needs. The company’s products comprise apokyn, myobloc and revonto. Its apokyn is used for …
  • Opus Energy Group Ltd:企業の戦略的SWOT分析
    Opus Energy Group Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • PT Garuda Indonesia (Persero) Tbk:企業の戦略・SWOT・財務情報
    PT Garuda Indonesia (Persero) Tbk - Strategy, SWOT and Corporate Finance Report Summary PT Garuda Indonesia (Persero) Tbk - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Energy Resources of Australia Ltd. (ERA):企業の財務・戦略的SWOT分析
    Energy Resources of Australia Ltd. (ERA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • AorTech International Plc (AOR):製薬・医療:M&Aディール及び事業提携情報
    Summary AorTech International plc (AorTech) is an Intellectual Property (IP) holding company. It develops and commercializes biologically stable polymers for next generation medical devices. It provides a broad range of polyurethane technologies for applications in cardiovascular surgery, interventi …
  • Sto SE & Co KGaA:企業の戦略・SWOT・財務情報
    Sto SE & Co KGaA - Strategy, SWOT and Corporate Finance Report Summary Sto SE & Co KGaA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Aeroflot Oao
    Aeroflot Oao - Strategy, SWOT and Corporate Finance Report Summary Aeroflot Oao - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Hybio Pharmaceutical Co Ltd (300199):製薬・医療:M&Aディール及び事業提携情報
    Summary Hybio Pharmaceutical Co Ltd (Hybio) is a peptide pharmaceutical company that develops and manufactures of polypeptide drugs. The company offers peptide finished dosage products and peptide active pharmaceutical ingredients. Its finished dosage products include desmopressin for injection, ter …
  • Valener Inc (VNR)-エネルギー分野:企業M&A・提携分析
    Summary Valener Inc (Valener) is an investment holding company that focuses on the energy sector. Through its investment companies, the company offers storage, distribution, transportation and allied energy services. The company has interests in Gaz Metro and is its limited partner. Valener, through …
  • InfuSystem Holdings Inc (INFU):企業の財務・戦略的SWOT分析
    Summary InfuSystem Holdings Inc (InfuSystem) is a provider of infusion pumps and related services. The company provides ambulatory infusion pumps and associated clinical services. Its patient services comprise infucare help hotline, infuease, education, and pain management. InfuSystem offers pumps a …
  • CDI Corp:企業の戦略的SWOT分析
    CDI Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Thi …
  • Immunomedics Inc (IMMU):企業の財務・戦略的SWOT分析
    Immunomedics Inc (IMMU) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Viridian Group Investments Ltd:企業の戦略的SWOT分析
    Viridian Group Investments Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major prod …
  • Astellas Pharma US Inc-製薬・医療分野:企業M&A・提携分析
    Summary Astellas Pharma US Inc (Astellas Pharma), a subsidiary of Astellas Pharma Inc is a drug company that offers injections and tablets. The company offers products such as adenosine injections, regadenoson injection, tacrolimus ointment, tacrolimus extended-release capsules, tacrolimus capsules …
  • Verso Corporation:企業の戦略・SWOT・財務情報
    Verso Corporation - Strategy, SWOT and Corporate Finance Report Summary Verso Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Atrium Innovations Inc-製薬・医療分野:企業M&A・提携分析
    Summary Atrium Innovations Inc (Atrium) is a provider of science-based natural health products. The company develops, manufactures and markets nutritional and dietary supplements. Its major products include minerals, vitamins and specialized products such as enzymes and probiotics. Atrium markets it …
  • Candover Investments plc (CDI):企業の財務・戦略的SWOT分析
    Candover Investments plc (CDI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Cree Inc (CREE):企業の財務・戦略的SWOT分析
    Cree Inc (CREE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆